BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16147904)

  • 1. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients.
    Zeng ZL; Sun J; Guo L; Li S; Wu MW; Qiu F; Jiang WQ; Lévi F; Xian LJ
    Chronobiol Int; 2005; 22(4):741-54. PubMed ID: 16147904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian variation of plasma cortisol and whole blood reduced glutathione levels in nasopharyngeal carcinoma patients.
    Wu MW; Zeng ZL; Li S; Guo L; Zhang JX; Qiu F; Xian LJ
    Ai Zheng; 2008 Mar; 27(3):237-42. PubMed ID: 18334110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
    Raida M; Kliche KO; Schwabe W; Häusler P; Clement JH; Behnke D; Höffken K
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):96-102. PubMed ID: 11862480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
    Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
    Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
    Furuhata T; Kawakami M; Okita K; Kimura Y; Kihara C; Tsuruma T; Ohmura T; Yamaguchi K; Hata F; Katsuramaki T; Sasaki K; Hirata K
    J Exp Clin Cancer Res; 2006 Mar; 25(1):79-82. PubMed ID: 16761622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The stability of dihydropyrimidine dehydrogenase activity in colorectal cancer tissue after resection.
    Sadahiro S; Suzuki T; Ishikawa K; Nakamura T; Kamijo A; Saguchi T; Yasuda S; Tajima T; Makuuchi H; Murayama C
    Oncol Rep; 2003; 10(4):867-9. PubMed ID: 12792736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y; Takahashi K; Saito T
    Hepatogastroenterology; 2005; 52(66):1715-21. PubMed ID: 16334763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian expression of dihydropyrimidine dehydrogenase, thymidylate synthase, c-myc and p53 mRNA in mouse liver tissue.
    Wu MW; Xian LJ; Li XM; Pasquale I; Francis L
    Ai Zheng; 2004 Mar; 23(3):235-42. PubMed ID: 15025949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy.
    Zhang R; Lu Z; Liu T; Soong SJ; Diasio RB
    Cancer Res; 1993 Jun; 53(12):2816-22. PubMed ID: 8504424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
    Jiang H; Lu J; Ji J
    Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors.
    Krugluger W; Brandstaetter A; Kállay E; Schueller J; Krexner E; Kriwanek S; Bonner E; Cross HS
    Cancer Res; 2007 Aug; 67(16):7917-22. PubMed ID: 17699798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
    Ogura K; Ohnuma T; Minamide Y; Mizuno A; Nishiyama T; Nagashima S; Kanamaru M; Hiratsuka A; Watabe T; Uematsu T
    Clin Cancer Res; 2005 Jul; 11(14):5104-11. PubMed ID: 16033824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].
    Xiao JX; Han M; Li L; Zhu J; Chen LH; Bai PS
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2136-9. PubMed ID: 16313827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.